Biomedical briefing.
- Published in:
- Nature Medicine, 2013, v. 19, n. 12, p. 1554, doi. 10.1038/nm1213-1554
- Publication type:
- Article
Works matching DE "TEVA Pharmaceuticals USA Inc."
Results: 21
1
2
RECENT DEVELOPMENTS IN PRODUCTS, GENERAL LIABILITY, AND CONSUMER LAW.
- Published in:
- Tort Trial & Insurance Practice Law Journal, 2010, v. 45, n. 2, p. 517
- By:
- Publication type:
- Article
3
Teva v FDA and Apotex v FDA: Two Court Decisions on the interpretation of a ‘Court Decision’.
- Published in:
- Journal of Generic Medicines, 2006, v. 3, n. 4, p. 306, doi. 10.1057/palgrave.jgm.4940133
- By:
- Publication type:
- Article
4
Teva v Pfizer: Creating an uncertain future for generics companies by de-modernising the Medicare Modernization Act.
- Published in:
- Journal of Generic Medicines, 2005, v. 2, n. 4, p. 351, doi. 10.1057/palgrave.jgm.4940088
- By:
- Publication type:
- Article
5
AZ's Seroquel faces competition.
- Published in:
- Chemistry & Industry, 2005, n. 20, p. 6
- By:
- Publication type:
- Article
6
SURVEY OF ADDITIONAL IP AND TECHNOLOGY LAW DEVELOPMENTS.
- Published in:
- Berkeley Technology Law Journal, 2018, v. 33, n. 4, p. 1343
- Publication type:
- Article
7
MISGUIDED PANIC AND MISSED OPPORTUNITY FOR PHARMACEUTICAL INVENTIONS: HOW UNEXPECTED RESULTS ECLIPSED REASONABLE EXPECTATION OF SUCCESS IN BMS V. TEVA.
- Published in:
- Berkeley Technology Law Journal, 2016, v. 31, p. 587, doi. 10.15779/Z38C85X
- By:
- Publication type:
- Article
8
INTELLECTUAL PROPERTY.
- Published in:
- Bench & Bar of Minnesota, 2017, v. 74, n. 5, p. 51
- By:
- Publication type:
- Article
9
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 10, p. 724, doi. 10.1038/nrd3574
- Publication type:
- Article
10
First-time generic approvals.
- Published in:
- Formulary, 2006, v. 41, n. 10, p. 491
- Publication type:
- Article
11
TEVA PHARMACEUTICALS USA TO PAY $2.25M CIVIL PENALTY FOR AIR, WATER, AND HAZARDOUS WASTE VIOLATIONS AT MEXICO, MO., FACILITY.
- Published in:
- Air Quality & Climate Change, 2013, v. 47, n. 2, p. EI-6
- Publication type:
- Article
12
Post-Mensing "Immunity" Under the Louisiana Products Liability Act: Johnson v. Teva Phaimaceuticals USA, Inc., and Its Implications for Louisiana Law.
- Published in:
- Tulane Law Review, 2015, v. 89, n. 4, p. 959
- By:
- Publication type:
- Article
13
from the FDA.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2006, v. 8, n. 11, p. 8
- Publication type:
- Article
14
From the FDA.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2006, v. 8, n. 10, p. 8
- Publication type:
- Article
15
FDA says Wellbutrin XL and generic bupropion XL are bioequivalent.
- Published in:
- Brown University Psychopharmacology Update, 2008, v. 19, n. 7, p. 8
- Publication type:
- Article
16
New drugs and dosage forms.
- Published in:
- 2009
- Publication type:
- Product Review
17
Giving Meaning to “Otherwise Available to the Public”: How Helsinn Perpetuates a Version of the On-Sale Bar to Patentability that Disproportionately Burdens Small Inventors.
- Published in:
- Texas Law Review, 2018, v. 97, n. 2, p. 421
- By:
- Publication type:
- Article
18
GENERIC DRUGS AND THE FUTURE OF "SKINNY LABELS".
- Published in:
- Harvard Journal of Law & Technology, 2022, v. 35, n. 2, p. 659
- By:
- Publication type:
- Article
19
Gene Splicing Creates Stronger Silk.
- Published in:
- AATCC Review, 2008, v. 8, n. 6, p. 15
- Publication type:
- Article
20
RESURRECTING THE PUBLIC VOICE: THE EXPANSION OF STANDING IN PATENT LITIGATION.
- Published in:
- Emory Law Journal, 2016, v. 65, n. 3, p. 893
- By:
- Publication type:
- Article
21
POZEN enters into settlement agreement with Teva.
- Published in:
- Journal of Intellectual Property Rights, 2010, v. 15, n. 3, p. 255
- Publication type:
- Article